Evolocumab

Evolocumab is an injectable cholesterol drug that lowers LDL by roughly 60%, far more than any pill, by blocking a protein called PCSK9. Most people end up on it because their LDL is still too high despite a statin (often plus ezetimibe) and they need a much bigger lever, or they genuinely can't tolerate statins and need strong LDL lowering without them. It's sold as Repatha, given as a self-injection every two weeks or once a month.

This is one of the few lipid drugs with hard outcome data behind it, not just a number on a lab report. In people with existing heart disease it cuts the risk of heart attacks, strokes, and the procedures that follow, and as of late 2025 it's also been shown to prevent first events in high-risk people who haven't had one yet. You won't feel anything taking it, the effect is entirely on your bloodwork and your long-term risk, and it's well tolerated. The main practical downsides are that it's an injection and it's expensive.

Deep-dive

PCSK9 is a protein your liver makes that acts like a wrecking crew for LDL receptors. LDL receptors sit on the surface of liver cells and pull LDL particles out of your blood. Normally a receptor grabs an LDL particle, drags it inside, drops it off, and goes back to the surface to do it again. PCSK9 interrupts that recycling: it binds the receptor and marks it for destruction, so instead of being reused, the receptor gets broken down. Fewer receptors means less LDL cleared from the blood. Evolocumab is a monoclonal antibody that binds circulating PCSK9 and takes it out of action, so LDL receptors survive longer, recycle more, and clear far more LDL. It reaches the same endpoint as a statin, more LDL receptors on the liver, but by a different route, which is why it stacks cleanly on top of statin therapy.

The magnitude is the headline. On top of a statin, evolocumab lowers LDL by around 60%, typically dropping people from the 90-110 mg/dL range down to 30-40 mg/dL. It also produces meaningful drops in ApoB and non-HDL cholesterol, a modest reduction in lipoprotein(a) of around 25%, a small triglyceride reduction, and a slight rise in HDL. The pooled phase 2 and 3 data show these reductions hold steady over years of use, with no tachyphylaxis, the body doesn't adapt around it.

Does it actually prevent events? This is the question that matters, because a drug can move a lab number without changing anything that happens to you. The FOURIER trial settled it for secondary prevention: 27,564 people with established atherosclerotic cardiovascular disease, already on statins, randomized to evolocumab or placebo and followed a median of 2.2 years. Evolocumab drove median LDL down to 30 mg/dL and cut the primary composite endpoint of cardiovascular death, heart attack, stroke, hospitalization for unstable angina, and coronary revascularization by 15%. Looking at the individual components, heart attack risk dropped about 27% and stroke about 21%. The benefit grew over time, the curves kept separating, which fits the idea that the longer you hold LDL low, the more plaque stabilizes.

One honest limitation of FOURIER: it did not show a reduction in cardiovascular death. The event reduction was real but driven by non-fatal events, and the 2.2-year follow-up was relatively short for a hard mortality signal. This is consistent with other intensive LDL-lowering trials and is generally attributed to short follow-up rather than absence of benefit, but it's a caveat worth knowing.

Plaque, directly imaged. The GLAGOV trial put a camera on it. 968 patients with coronary disease on statins got evolocumab or placebo, with the artery wall measured by intravascular ultrasound before and after 76 weeks. Evolocumab produced actual regression of coronary plaque, and a greater proportion of patients showed regression than on statin alone. It also showed that benefit continued down to very low LDL levels, with no obvious floor where lowering stopped helping.

Long-term data. The FOURIER open-label extension followed 6,635 patients out to a maximum evolocumab exposure of 8.4 years. LDL reductions stayed stable, the safety profile held with no new signals emerging over time, and the people who started evolocumab earliest accrued the most benefit. The practical read is that this is a drug you stay on indefinitely, the way statin users do, and the long arc of data supports that.

Primary prevention. For years the outcome evidence was confined to people who'd already had an event. The VESALIUS-CV trial, published November 2025, extended it: 12,257 high-risk patients with atherosclerosis or diabetes but no prior heart attack or stroke, on optimized lipid-lowering therapy, randomized to evolocumab or placebo and followed a median of 4.6 years. Evolocumab cut the risk of a first major cardiovascular event (coronary death, heart attack, ischemic stroke) by 25%, and first heart attack specifically by 36%, with no new safety concerns. This meaningfully widens who has real evidence behind using it, though "high-risk" is doing work in that sentence, the trial population was selected for elevated LDL plus established atherosclerosis or diabetes, not the general population.

Statin-intolerant patients. The GAUSS-3 trial tackled the muscle-symptom population. It first used a blinded crossover to confirm who genuinely had statin-associated muscle symptoms (about 43% did, the rest had symptoms on placebo too, the nocebo effect is large here), then randomized the confirmed group to evolocumab or ezetimibe. Evolocumab lowered LDL by about 53% versus about 17% for ezetimibe, and discontinuation for muscle symptoms was rare. For someone who truly can't take a statin, evolocumab is the most effective LDL lever available.

Women. Women made up about a quarter of FOURIER, and a prespecified analysis by age and sex found the relative risk reductions in women were essentially the same as in men, for both the primary endpoint and the harder cardiovascular death/MI/stroke endpoint. The LDL lowering itself is no different by sex. VESALIUS-CV was 43% women, a notably better representation than most cardiovascular trials, and the benefit held. The practical relevance is real: women are consistently undertreated for cholesterol and more likely to come off statins due to side effects, so a drug that works equally well and is easy to tolerate matters for closing that gap. One safety note from the FOURIER analysis, adverse events overall were somewhat more common in women and with older age, but apart from injection site reactions there were no important between-group differences, meaning the extra events weren't caused by evolocumab. Evolocumab is not used in pregnancy or breastfeeding, lipid-lowering drugs are generally paused during this period and there's no adequate human safety data, although it's worth knowing that as a large antibody it isn't expected to cross the placenta much in the first trimester.

Older adults. Roughly 9% of FOURIER was 75 or older, and combined FOURIER and FOURIER-OLE data in elderly patients found consistent cardiovascular benefit with early initiation and no significant safety concerns specific to age. Because evolocumab doesn't carry the myopathy and drug-interaction baggage that high-intensity statins do, it's a sensible way to reach LDL targets in older people without escalating statin dose. No dose adjustment for age, and none for kidney impairment either.

The diabetes question. Statins carry a small, real signal for new-onset diabetes, so this was checked carefully for PCSK9 inhibitors. In the prespecified FOURIER diabetes analysis, evolocumab did not increase new-onset diabetes, including in people with prediabetes, and didn't worsen HbA1c or fasting glucose. People with diabetes actually got a larger absolute benefit because their baseline risk was higher. The one nuance worth stating honestly: Mendelian randomization studies, which look at people with naturally low PCSK9 from genetics, have suggested a small increased diabetes risk, and the trial follow-up may be too short to fully rule out a tiny effect. The trial evidence is reassuring; the genetic data is a mild asterisk.

Cognitive safety. Because evolocumab pushes LDL to levels rarely seen before, there was a theoretical worry about the brain, which is cholesterol-rich. The EBBINGHAUS trial tested this directly, a prespecified study within FOURIER using validated cognitive testing in 1,974 patients. Over a median of 19 months there was no difference in executive function, working memory, episodic memory, or psychomotor speed, including in patients who reached LDL below 25 mg/dL. The long-term extension, following a subset out to roughly 7 years, found the same: no association between very low LDL achieved through PCSK9 inhibition and cognitive impairment. This is about as well-studied as the question gets.

Limitations of the evidence. The big outcome trials were funded by the manufacturer, which is normal for drugs at this stage but worth noting. The hard endpoint data is strongest in selected populations: established atherosclerotic disease in FOURIER, high-risk atherosclerosis or diabetes in VESALIUS-CV. There's no outcome trial in genuinely low-risk people and there shouldn't be, the absolute benefit there would be tiny. Cardiovascular mortality specifically has not been shown to drop, likely a follow-up-duration issue but unresolved. And the practical limitation outside the science is cost and access, this is an expensive biologic and insurance coverage often gates who actually gets it.

Dosage:

Two equivalent regimens: 140 mg every 2 weeks, or 420 mg once monthly. Both lower LDL by about the same amount, pick based on what you'll actually remember and stick to. Many people prefer the monthly dose for convenience

Given as a subcutaneous self-injection, into the abdomen, thigh, or back of the upper arm. The 140 mg dose comes as a single prefilled autoinjector or syringe. The 420 mg monthly dose is either three 140 mg injections done back-to-back within 30 minutes, or a single on-body infusor

Rotate injection sites and don't inject into skin that's bruised, red, tender, or hard. Let the pen warm to room temperature before injecting, it stings less and is more comfortable

It's almost always an add-on, not a replacement. Keep your statin (and ezetimibe, if you're on it) going, evolocumab stacks on top. The exception is genuine statin intolerance, where it's used without a statin, often alongside ezetimibe

Give it 4-8 weeks before checking a lipid panel. The LDL effect shows up fast but you want a stable read. If you're on the monthly 420 mg dose, time the blood draw just before your next injection, since levels dip slightly across the month

Same dose regardless of sex, age, or kidney function. No adjustment needed. People on lipid apheresis sometimes start at 420 mg every 2 weeks to match the apheresis schedule, that's a specialist decision

Storage matters: it's a biologic, keep it refrigerated. It can sit at room temperature but only for up to 30 days, then it has to be discarded

This is a long-term drug. LDL returns to baseline within weeks of stopping, the same way it does with statins, so it's only worth taking if you plan to stay on it

Here's what you can expect:

You will not feel anything. Evolocumab has no perceptible day-to-day effect, no energy change, nothing you'd notice. The only evidence it's working is a blood test, and on that test the change is dramatic: LDL roughly 60% lower, usually landing in the 30-40 mg/dL range, showing up within the first few weeks and stable from then on.

The thing you might notice is at the injection site, mild redness, an itch, or tenderness for a day or so. It's the most common real effect and usually fades as you get used to the technique.

Everything else is invisible and long-term: a lower heart attack and stroke risk that compounds the longer you stay on it, and, if it were imaged, slow regression of arterial plaque. This is a number-mover and a risk-mover, not something you experience.

Side effects & risks:

It's well tolerated. Across the large trials the overall adverse event profile was close to placebo, and crucially, it does not cause the muscle symptoms that drive people off statins

Injection site reactions are the most common real complaint, redness, itching, tenderness, occasionally mild swelling. Usually minor, usually settle with site rotation and good technique. This was the one adverse event consistently higher than placebo in the trials

Flu-like symptoms, headache, back pain, and nasopharyngitis-type complaints show up occasionally, generally mild and not clearly above placebo rates

Allergic reactions are uncommon but possible with any injectable antibody, ranging from rash to, very rarely, more serious hypersensitivity. Stop and seek care if you get a serious reaction

Diabetes: the trial data shows no increase in new-onset diabetes or worsening glucose control. Genetic (Mendelian randomization) data hints at a small possible effect, so it's reasonable to keep an eye on glucose if you're prediabetic, but the clinical evidence is reassuring

Cognition: prospectively tested down to very low LDL and out to several years, with no signal. This was a theoretical concern that the evidence has largely put to rest

Very low LDL: evolocumab routinely produces LDL levels below anything seen with statins alone. The outcome and safety data at these levels is reassuring so far, but it's a relatively new place for medicine to be and very long-term data is still accumulating

No significant drug interactions. As an antibody it's cleared differently from small-molecule drugs and doesn't tangle with the CYP450 system, so it doesn't interfere with other medications

Pregnancy and breastfeeding: not used. No adequate human data, and lipid-lowering therapy is generally paused during this period

Anti-drug antibodies can form against any biologic, but with evolocumab neutralizing antibodies that would blunt its effect have not been a meaningful clinical problem

🩸

Blood markers

Full lipid panel (LDL, HDL, triglycerides, total cholesterol), baseline and again at 4-8 weeks. This is the only way to confirm evolocumab is working, since you won't feel it. ApoB and non-HDL cholesterol are better markers than LDL alone if you can get them, they track the actual atherogenic particle burden, and lipoprotein(a) is worth measuring once at baseline since evolocumab lowers it modestly. On the monthly 420 mg regimen, draw the panel just before the next dose.

HbA1c or fasting glucose, baseline. Not because evolocumab clearly raises glucose, the trial data says it doesn't, but a baseline is sensible if you're prediabetic or diabetic, given the residual uncertainty from genetic studies.

Liver enzymes (ALT, AST), baseline. Mostly relevant because of the background statin rather than evolocumab itself, but a baseline is standard before starting combination lipid therapy.

Recheck the lipid panel periodically once stable, every 6-12 months, to confirm you're holding target. No specialized monitoring schedule beyond that, evolocumab doesn't require the CK, copper, or other targeted bloodwork some compounds do.

Who actually needs what: anyone starting evolocumab should get a baseline lipid panel (ideally with ApoB) and have it rechecked at 4-8 weeks, that's the core. Liver enzymes and glucose at baseline are sensible but low-effort. If you're statin-intolerant and on evolocumab as monotherapy, the lipid panel is essentially the whole monitoring picture.

Evolocumab is a prescription medication. The information here is educational and not a substitute for individualised medical advice.